Notes to the unaudited interim condensed consolidated statement of financial position (Tables)

6 Months Ended

Jun. 30, 2026

Notes to the unaudited interim condensed consolidated statement of financial position

Schedule of intangible assets


In thousands of euros		December 31, 2025		June 30, 2026
Intangible assets, gross		4,094		4,230
Amortization and impairment		(3,911)		(3,920)
Intangible assets, net		182		310

Reconciliation of changes in property, plant and equipment


In thousands of euros		December 31, 2025		June 30, 2026
Property, plant and equipment, gross		19,939		17,952
Depreciation and impairment		(16,960)		(15,592)
Property, plant and equipment, net		2,979		2,360

Schedule of investment in Hepalys is accounted for using the equity method of accounting


(in thousands of euros)		December 31, 2025		June 30, 2026
Non-current assets		12,729		11,556
Current assets		183		1,966
Total assets		12,912		13,522
Shareholders’ equity		12,766		13,389
Current liabilities		146		133
Equity and liabilities		12,912		13,522
Opening net assets		18,368		12,766
Loss for the period⁽¹⁾		(3,816)		(1,642)
Other comprehensive income		(1,786)		(70)
Capital variations		—		2,335
Closing net assets		12,766		13,389
Group’s share in %		15	%	14	%
Group’s share		1,869		1,832
Elimination of unrealized profit on downstream sales		(1,378)		(1,340)
Goodwill		37		37
Carrying amount		527		528

(1)	Refer to Note 5.5 – Share of net profit - equity method

Schedule of other non current assets


(in thousands of euros)		December 31, 2025		June 30, 2026
Long-term deposit accounts		115		836
Advance payments – non-current		1,047		1,047
Allowance for doubtful accounts		—		(33)
Other non‑current assets		1,162		1,849

Schedule of trade receivables and others break down


(in thousands of euros)		December 31, 2025		June 30, 2026
3 months or less		2,016		3,734
Trade receivables and others		2,016		3,734

Schedule of other current assets and receivables


(in thousands of euros)		December 31, 2025		June 30, 2026
CIR and other research tax credits		2,267		3,080
Other		14		3
Tax receivables		2,281		3,083
Prepaid expenses		3,952		1,660
Short-term deposit accounts		131,558		67,765
Current accrued income		1,575		862
Liquidity agreement - Cash		527		—
VAT receivables		3,148		2,677
Other receivables		101		57
Other current assets		140,861		73,021
Other current assets and tax receivables		143,142		76,104

Schedule of cash and cash equivalents balance from the statement of cash flows


(in thousands of euros)		December 31, 2025		June 30, 2026
Other cash equivalents ⁽¹⁾		82,628		132,293
Cash at bank and at hand		16,684		33,835
Cash and cash equivalents ⁽²⁾		99,312		166,127
Cash and cash equivalents balance from the statement of cash flows		99,312		166,127

(1)	Other cash equivalents correspond to short - term bank deposits

(2)	Balances presented in the statement of financial position

Schedule of changes in share capital


						Premiums
(In euros, except number of shares)				Share		related to		Number of		Nominal
Date		Nature of the transactions		capital		share capital		shares		value
Balance as of December 31, 2025				1,932,370		528,230,262		193,236,978		0.01
January 1, 2026		Transaction costs related to the Public offering (American Depositary Shares) of November 18, 2025		—		(428,028)		—		—
January 14, 2026		Structured Financing (Exercise of T1bis warrants)		20,594		2,759,577		2,059,386		0.01
January 23, 2026		Structured Financing (Exercise of T2 warrants)		111,111		14,888,889		11,111,111		0.01
February 11, 2026		Structured Financing (Exercise of T1 warrants)		13,000		1,742,000		1,300,000		0.01
April 23, 2026		Structured Financing (Exercise of T1 warrants)		13,000		1,742,000		1,300,000		0.01
June 5, 2026		Equity Offering		272,727		94,989,798		27,272,727		0.01
Balance as of June 30, 2026				2,362,802		643,924,498		236,280,202		0.01

Schedule of stock option plans


		Decision of				Fair value		Outstanding								Outstanding
		issuance by the		Grant		at grant date		at Jan 1,						Forfeited /		at June 30,
Type		Board of Directors		Date		(in euros)		2026		Issued		Exercised		Lapsed		2026
SO 2024-1		12/20/2024		01/23/2025		1.10		12,898,116		—		—		—		12,898,116
SO 2024-2		12/20/2024		01/23/2025		1.10		213,000		—		—		—		213,000
SO 2025-1		10/10/2025		10/10/2025		1.77		1,865,750		—		—		(7,500)		1,858,250
SO 2025-2		12/02/2025		12/04/2025		1.78		6,000,000		—		—		—		6,000,000
SO 2025-3		12/15/2025		01/26/2026		3.68		1,145,500		—		—		—		1,145,500
SO 2026-1		06/09/2026		06/09/2026		1.68		—		1,067,000		—		—		1,067,000
SO 2026-2		06/30/2026		07/07/2026		1.83		—		3,000,000		—		—		3,000,000
TOTAL Stock options								22,122,366		4,067,000		—		(7,500)		26,181,866

Schedule of valuation approach for European investment bank warrants


		As of June 30, 2026
		(Shareholders approval
New EIB Warrants		and valuation date)
Number of warrants outstanding		15,677,573
Number of shares per warrant		1.00
Stock price (€)		3.22
Maturity (years)		9.5
Volatility		58.6	%
Strike price (€)		0.01
Risk free rate		3.7	%
Expected dividends		—
Fair Value (k€)		50,400
Unit Fair value (€)		3.21

Schedule of Debt, Derivatives and Royalty Certificates liabilities


						Debt carried on the
June 30, 2026						balance sheet on
(in thousands of euros)		Short-term		Long-term		June 30, 2026
Bank borrowings		10,716		52,994		63,710
Accrued interest payable on loans		624		—		624
Lease liabilities		1,974		351		2,325
Debt		13,314		53,345		66,659
Derivatives		—		13,051		13,051
Royalty certificates liabilities		—		59,079		59,079
Total		13,314		125,475		138,789


						Debt carried on the
December 31, 2025						balance sheet on
(in thousands of euros)		Short-term		Long-term		December 31, 2025
Bank borrowings		29,836		21,398		51,234
Accrued interest payable on loans		436		5,418		5,855
Lease liabilities		2,036		735		2,771
Debt		32,309		27,551		59,860
Derivatives		—		119,385		119,385
Royalty certificates liabilities		—		51,645		51,645
Total		32,309		198,581		230,890

Schedule of changes in liabilities


		Bank borrowings												Derivatives
				PGE				BlackRock -		Accrued						Convertible
				&				Claret		interest						option				Royalty
		Bank		PPR		EIB		Tranche		payable		Lease		EIB		(Convertible		Lenders		certificates
In thousands of euros		overdraft		Loans		loan		A & B		on loans		liabilities		Warrants		Bonds)		Warrants		liabilities		Total
As of December 31, 2025		13		5,928		45,292		—		5,855		2,771		119,385		—		—		51,645		230,890
Principal received		(13)		—		—		59,015		—		—		—		10,588		—		—		69,589
Decrease in loans		—		(1,478)		(50,000)		—		—		—		(50,000)		—		—		—		(101,478)
Interest paid		—		(75)		(12,204)		(392)		—		—		—		—		—		—		(12,671)
Payment of lease liabilities		—		—		—		—		—		(1,167)		—		—		—		—		(1,167)
Cash flow from (used in) financing activities		(13)		(1,553)		(62,204)		58,623		—		(1,167)		(50,000)		10,588		—		—		(45,726)
Lease new contract / reassessment		—		—		—		—		—		671		—		—		—		—		671
Initital recognition at fair value		—		—		—		—		—		—		—		—		3,784		—		3,784
Change in fair value		—		—		—		—		—		—		(69,385)		(1,012)		(309)		—		(70,705)
Cumulative fixed interest expense accrual		—		75		11,394		637		(5,231)		48		—		—		—		7,433		14,374
Catch-up impact of the debt remeasurement		—		—		5,517		—		—		—		—		—		—		—		5,500
Foreign exchange gain (loss)		—		—		—		—		—		2		—		—		—		—		2
Non-cash from (used in) financing activities		—		75		16,912		637		(5,231)		721		(69,385)		(1,012)		3,475		7,433		(46,375)
As of June 30, 2026		—		4,450		—		59,260		624		2,325		—		9,576		3,475		59,079		138,789


		Bank borrowings										Derivatives
												T2
												New
												Shares
								Accrued				and T2
				PGE				interest				BSAs				Royalty
		Bank		&		EIB		payable		Lease		call		EIB		certificates
In thousands of euros		overdraft		PPR Loans		loan		on loans		liabilities		options		Warrants		liabilities		Total
As of December 31, 2024		9		9,195		35,993		4,477		4,654		73,400		24,315		29,207		181,250
Principal received		3		—		—		—		—		—		—		—		3
Decrease in loans		—		(1,791)		—		—		—		—		—		—		(1,791)
Payment of lease liabilities		—		—		—		—		(1,317)		—		—		—		(1,317)
Cash flow from (used in) financing activites		3		(1,791)		—		—		(1,317)		—		—		—		(3,104)
Lease new contract / reassessment		—		—		—		—		739		—		—		—		739
Change in fair value		—		—		—		—		—		(73,400)		17,936		—		(55,464)
Cumulative fixed interest expense accrual		—		—		4,286		933		—		—		—		4,208		9,427
Foreign exchange gain (loss)		—		—		—		—		(49)		—		—		—		(49)
Non-cash from (used in) financing activites		—		—		4,286		933		690		(73,400)		17,936		4,208		(45,347)
As of June 30, 2025		12		7,404		40,279		5,410		4,027		—		42,251		33,415		132,798

Schedule of valuation approach for EIB warrants


		Tranche A EIB		Tranche B EIB
		Warrants (2022)		Warrants (2024)
Grant date		11/28/2022		01/04/2024
Expiration date		11/28/2034		01/04/2036
Number of warrants issued		2,266,023		3,144,654
Number of shares per BSA		1		1
Subscription premium price per share (€)		0.01		0.01
Exercise price per share (€)		4.02		3.95
Valuation method		Longstaff Schwartz		Longstaff Schwartz


						As of June 1, 2026
		As of November 28, 2022				(EIB Transactions
Tranche A EIB Warrants (2022)		(Grant Date)		As of December 31, 2025		Execution Date)
Number of warrants outstanding		2,266,023		2,266,023		2,266,023
Number of shares per warrant		1.00		6.46		6.46
Stock price (€)		4.13		3.95		4.19
Maturity (years)		12		8.9		8.5
Volatility		68	%	56.2	%	56.8	%
Cap of the put option (k€)		25.0		25.0		25.0
Risk free rate		Euribor 6M		Euribor 6M		Euribor 6M
Expected dividends		—		—		—
Fair Value (k€)		9,469		61,004		66,256
Unit Fair value (€)		4.18		26.92		29.24


						As of June 1, 2026
		As of January 4, 2024				(EIB Transactions
Tranche B EIB Warrants (2024)		(Grant Date)		As of December 31, 2025		Execution Date)
Number of warrants outstanding		3,144,654		3,144,654		3,144,654
Number of shares per warrant		1.00		5.05		5.05
Stock price (€)		4.12		3.95		4.19
Maturity (years)		12		10.0		9.6
Volatility		62	%	56.2	%	56.8	%
Cap of the put option (k€)		25.0		25.0		25.0
Risk free rate		Euribor 6M		Euribor 6M		Euribor 6M
Expected dividends		—		—		—
Fair Value (k€)		11,809		58,381		61,698
Unit Fair value (€)		3.76		18.57		19.62

Schedule of valuation approach for lenders' warrants


		As of June 12, 2026		As of June 30, 2026
Lenders’ Warrants		(Grant date)		(Valuation date)
Number of warrants outstanding		1,624,196		1,624,196
Number of shares per warrant		1.00		1.00
Stock price (€)		3.42		3.22
Maturity (years)		10.0		10.0
Volatility		58.9	%	58.6	%
Strike price (€)		4.16		4.16
Risk free rate		3.9	%	3.7	%
Expected dividends		—		—
Fair Value (k€)		3,784		3,476
Unit Fair value (€)		2.33		2.14

Schedule of provisions


						Reversals		Reversals
(in thousands of euros)		January 1, 2026		Additions		used		unused		June 30, 2026
Short-term provisions		1,071		614		(705)		—		980
Total Provisions		1,071		614		(705)		—		980

Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period


(in thousands of euros)		December 31, 2025		June 30, 2026
Retirement benefit obligations		755		680
Total obligation		755		680

Schedule of change in the provision recorded in respect of defined benefit schemes


(in thousands of euros)		June 30, 2025		June 30, 2026
Provision at beginning of period		(1,762)		(755)
Gain / (Expense) for the period		778		2
Actuarial gains or losses recognized in other comprehensive income		93		73
Provision at end of period		(891)		(680)

Schedule of breakdown of expense recognized for the period


(in thousands of euros)		June 30, 2025		June 30, 2026
Service cost for the period		(106)		(64)
Interest cost for the period		(30)		(15)
Past service costs		747		—
Benefits for the period		167		82
Plan curtailments and modifications		—		—
Total		778		2

Schedule of other current liabilities


(in thousands of euros)		December 31, 2025		June 30, 2026
Employee-related payables		2,734		2,960
Accrued payroll and other employee-related taxes		10,739		11,212
VAT payables		1,622		1,116
Other accrued taxes and employee-related expenses		148		284
Other miscellaneous payables		2,738		190
Other current liabilities		17,981		15,761

Schedule of trade payables and other current liabilities


(in thousands of euros)		December 31, 2025		June 30, 2026
Trade payables		26,017		34,532
Trade payables and other current liabilities		26,017		34,532

Schedule of trade payables break down by payment


(in thousands of euros)		December 31, 2025		June 30, 2026
Due in 30 days		24,770		32,811
Due in 30-60 days		1,247		215
Due in more than 60 days		—		1,506
Trade payable		26,017		34,532

Schedule of financial assets and liabilities


		June 30, 2026
				Financial
		Book value		assets/liabilities		Financial
		on the		carried at		assets		Liabilities
		statement		fair value		carried at		carried at
		of financial		through		amortized		amortized
Financial assets		position		profit or loss		cost		cost		Fair value
Long-term deposit accounts ⁽²⁾		836		—		836		—		836
Current accrued income ⁽¹⁾		862		—		862		—		862
Short-term deposit accounts ⁽¹⁾		67,765		—		67,765		—		67,765
Trade receivables ⁽¹⁾		3,734		—		3,734		—		3,734
Other receivables ⁽¹⁾		57		—		57		—		57
Cash and cash equivalents ⁽³⁾		166,127		—		166,127		—		166,127
Total		238,381		—		239,381		—		239,381

Financial liabilities
Long-term debt ⁽⁴⁾⁽⁵⁾		53,345		—		—		53,345		53,981
Derivative instruments ⁽⁶⁾		13,051		13,051		—		—		13,051
Royalty certificates liabilities ⁽⁴⁾		59,079		—		—		59,079		154,396
Short-term debt ⁽¹⁾		13,314		—		—		13,334		13,314
Trade payables ⁽¹⁾		34,532		—		—		34,532		34,532
Other miscellaneous payables ⁽¹⁾		190		—		—		190		190
Total		173,512		13,051		—		160,460		269,465

(1)	The carrying amount of short-term financial assets and liabilities at amortized cost is considered a reasonable estimate of fair value, in accordance with IFRS 7.29.

(2)	The fair value of long-term deposit accounts is determined using a discounted cash flow model based on the contractual reimbursement amount and the estimated market discount rate applicable, therefore classified within level 3 IFRS 13 fair value hierarchy.

(3)	The carrying amount of cash and cash equivalents is based on level 1 valuation and corresponds to the fair value of the assets.

(4)	The fair value of royalty certificates, the Lenders’ Tranche A and the Lenders’ Tranche B, accounted for at amortized cost, is determined using level 3 valuation based on unobservable inputs, as described in Note 4.9 – Debt, derivatives and royalty certificates liabilities.

(5)	The classification of other bank borrowings within the IFRS 13 fair value hierarchy corresponds to a level 3 valuation.

(6)

The fair value of derivative instruments, including the conversion option embedded in the Convertible Bonds, the Lenders’ Warrants, is determined using valuation techniques based on significant unobservable inputs and is therefore classified within Level 3 of the IFRS 13 fair value hierarchy. Further information is provided in Note 4.9 – Debt, derivatives and royalty certificates liabilities.


		December 31, 2025
				Financial
		Book value		assets/liabilities		Financial
		on the		carried at		assets		Liabilities
		statement		fair value		carried at		carried at
		of financial		through		amortized		amortized
Financial assets		position		profit or loss		cost		cost		Fair value
Long-term deposit accounts		115		—		115		—		115
Current accrued income⁽¹⁾		1,575		—		1,575		—		1,575
Short-term deposit accounts⁽¹⁾		131,558		—		131,558		—		131,558
Trade receivables⁽¹⁾		2,016		—		2,016		—		2,016
Other receivables⁽¹⁾		1,919		—		1,919		—		1,919
Cash and cash equivalents⁽²⁾		99,312		—		99,312		—		99,312
Total		236,494		—		236,494		—		236,494

Financial liabilities
Long-term debt⁽³⁾⁽⁴⁾		27,609		—		—		27,609		27,609
Derivative instruments⁽⁵⁾		119,385		119,385		—		—		119,385
Royalty certificates liabilities⁽³⁾		51,645		—		—		51,645		154,996
Short-term debt⁽¹⁾		32,309		—		—		32,309		32,309
Trade payables⁽¹⁾		26,017		—		—		26,017		26,017
Other miscellaneous payables⁽¹⁾		2,738		—		—		2,738		2,738
Total		259,704		119,385		—		140,319		363,055

(1)	The carrying amount of short-term financial assets and liabilities at amortized cost is considered a reasonable estimate of fair value, in accordance with IFRS 7.29.

(2)	The carrying amount of cash and cash equivalents is based on level 1 valuation and corresponds to the fair value of the assets.

(3)	The fair value of royalty certificates and EIB financial debt, accounted for at amortized cost, is determined using level 3 valuation based on unobservable inputs, as described in Note 4.9 – Debt, derivatives and royalty certificates liabilities.

(4)	The classification of other bank borrowings within the IFRS 13 fair value hierarchy corresponds to a level 2 valuation.

(5)	The fair value of derivative instruments is determined using level 3 valuation based on unobservable inputs, as described in Note 4.9 – Debt, derivatives and royalty certificates liabilities.

BSPCE share warrants and BSA share warrants

Notes to the unaudited interim condensed consolidated statement of financial position

Schedule of movements in BSPCE and BSA share warrants and AGA


		Decision of issuance				Exercise		Outstanding								Outstanding		Number of
		by the Board				price		at Jan 1,						Forfeited /		at June 30,		exercisable
Type		of Directors		Grant Date		(in euros)		2026		Issued		Exercised		Lapsed		2026		shares
BSPCE - Plan 2021		04/16/2021		04/16/2021		11.74		430,000		—		—		—		430,000		430,000
TOTAL BSPCE share warrants								430,000		—		—		—		430,000		430,000
BSA - Plan 2017		05/29/2017		05/29/2017		6.67		130,000		—		—		—		130,000		130,000
BSA - Plan 2018		12/14/2018		12/14/2018		6.07		116,000		—		—		—		116,000		116,000
BSA 2019		06/28/2019		06/28/2019		2.20		10,000		—		—		—		10,000		10,000
BSA 2019 bis		03/09/2020		03/09/2020		3.68		10,000		—		—		—		10,000		10,000
BSA 2019 ter		03/09/2020		03/09/2020		3.68		36,000		—		—		—		36,000		36,000
BSA 2021		04/16/2021		04/16/2021		11.74		14,333		—		—		—		14,333		14,333
BSA 2023		05/25/2023		05/25/2023		2.51		10,000		—		—		—		10,000		—
BSA 2023 - 2		12/15/2023		12/15/2023		3.91		20,000		—		—		—		20,000		—
BSA 2026		06/30/2026		06/30/2026		3.28		—		300,000		—		—		300,000		300,000
TOTAL BSA share warrants								346,333		300,000		—		—		646,333		616,333
Total share warrants								776,333		300,000		—		—		1,076,333		1,046,333

AGA

Notes to the unaudited interim condensed consolidated statement of financial position

Schedule of movements in BSPCE and BSA share warrants and AGA


		Decision of issuance				Stock price		Outstanding								Outstanding
		by the Board				at grant date		at Jan 1,						Forfeited /		at June 30,
Type		of Directors		Grant Date		(in euros)		2026		Granted		Vested		Lapsed		2026
AGA 2023-1		05/25/2023		05/25/2023		2.60		385,706		—		—		—		385,706
AGA 2024-1 (Tr1 - Tr2 - Tr3)		12/13/2024		01/06/2025		2.30		276,849		—		—		—		276,849
AGA 2024-2 (Tr1 - Tr2 - Tr3)		12/13/2024		01/06/2025		2.30		113,179		—		—		—		113,173
AGA 2024-3 (Tr1 - Tr2 - Tr3)		12/13/2024		01/06/2025		2.30		975,043		—		—		(29,749)		945,294
AGA 2024-4 (Tr1 - Tr2 - Tr3)		12/13/2024		01/17/2025		2.30		113,000		—		—		(23,183)		89,817
AGA 2025-1 (Tr1 - Tr2 - Tr3)		09/30/2025		09/30/2025		3.67 - 4.92		1,588,663		—		—		—		1,588,663
AGA 2025-1 (Tr4)		09/30/2025		09/30/2025		3.61 - 4.76		630,070		—		—		—		630,070
AGA 2025-2		09/26/2025		09/26/2025		4.95		2,298,000		—		—		(74,601)		2,223,399
AGA 2025-4		12/15/2025		12/15/2025		3.79		68,000		—		—		(5,000)		63,000
AGA 2025-5		12/15/2025		12/15/2025		3.79		500,000		—		—		—		500,000
AGA 2026-1		03/27/2026		03/27/2026		5.15		—		434,000		—		(5,000)		429,000
AGA 2026-1bis		03/27/2026		03/27/2026		5.15		—		38,000		—		—		38,000
AGA 2026-2		05/01/2026		05/01/2026		4.31		—		137,500		—		—		137,500
AGA 2026-2bis		05/01/2026		05/01/2026		4.31		—		450,000		—		—		450,000
TOTAL free shares								6,948,504		1,059,500		—		(137,533)		7,870,471

Schedule of main characteristics of share-based payment plan


		AGA 2026-1		AGA 2026-1bis		AGA 2026-2		AGA 2026-2bis
		(Tr1 - Tr2 - Tr3)		(Tr1 - Tr2 - Tr3)		(Tr1 - Tr2 - Tr3)		(Tr1 - Tr2 - Tr3)
Decision of issuance by the Board of Directors		03/27/2026		03/27/2026		05/01/2026		05/01/2026
Grant date		03/27/2026		03/27/2026		05/01/2026		05/01/2026
Beneficiary		Employees and Susan Coles (Chief Legal Officer)		Employees		Employees		Axel-Sven Malkomes (Chief Financial Officer)
Holding period (year)		3		3		3		3
Service condition		Yes		Yes		Yes		Yes
Performance condition		No		No		No		No
Number of AGA granted		434,000		38,000		137,500		450,000
Number of shares per AGA		1		1		1		1
Valuation method used		Share price		Share price		Share price		Share price
Fair value per AGA at grant date		5.15		5.15		4.31		4.31
Expected volatility		N/A		N/A		N/A		N/A
Average life (years)		N/A		N/A		N/A		N/A
Risk-free rate		N/A		N/A		N/A		N/A
Expected dividends		—		—		—		—
Stock price reference		N/A		N/A		N/A		N/A
Non-transferable discount		N/A		N/A		N/A		N/A

Stock options

Notes to the unaudited interim condensed consolidated statement of financial position

Schedule of measurements for share options granted


		SO 2025-3		SO 2026-1		SO 2026-2
Decision of issuance by the Board of Directors		12/15/2025		06/09/2026		06/30/2026
Grant date		01/26/2026		06/09/2026		07/07/2026
Beneficiary		Employees		Employees and Pamela Herbster, (Chief People Officer)		Mark Pruzanski (Chairman of the Board of Directors)
Vesting period (year)		3		3		1.5
Holding period (year)		1		1		1
Service condition		Yes		Yes		Yes
Performance condition		No		No		Yes
Number of SO granted		1,145,500		1,067,000		3,000,000
Number of shares per SO		1		1		1
Valuation method used		Black & Scholes		Black & Scholes		Black & Scholes
Fair value per SO at grant date		3.68		1.68		1.83
Expected volatility		57.3	%	59.0	%	58.7	%
Average life (years)		5		5		5
Risk-free rate		2.7	%	3.1	%	3.1	%
Expected dividends		—		—		—
Stock price reference		3.63	€	3.26	€	3.33	€
Non-transferable discount		N/A		N/A		N/A